![](https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png)
FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19 The U.S. Food and Drug Administration today revised the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) authorizing REGEN-COV …